Last reviewed · How we verify
NCT05107869
Effect of Plasma Ceramides on Peripheral Vascular Function
NA trial testing High Saturated Fat in Peripheral Vascular Disease in 23 participants. Completed in 7 May 2025.
7 May 2025
Quick facts
| Lead sponsor | Medical College of Wisconsin |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | basic science |
| Enrollment | 23 |
| Start date | 1 May 2023 |
| Primary completion | 7 May 2025 |
| Estimated completion | 7 May 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- High Saturated Fat
Conditions studied
- Peripheral Vascular Disease — all drugs for Peripheral Vascular Disease →
- Lipid Disorder — all drugs for Lipid Disorder →
- Endothelial Dysfunction — all drugs for Endothelial Dysfunction →
Sponsor
Medical College of Wisconsin
Who can join
Adults 18 to 40, any sex, with Peripheral Vascular Disease or Lipid Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to determine the effect of elevated plasma ceramides on peripheral vascular function. Subjects will consume a high fat meal consisting of long chain fatty acids (to increase plasma ceramides) or medium chain fatty acids (control). Subjects' vascular function will be assessed with laser Doppler flowmetry to measure their artery function and with the CytoCam device to assess their peripheral microvascular endothelial function.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05107869
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Peripheral Vascular Disease
Currently open trials in the same condition.
- NCT06686121 — Improving Mobility After Revascularization in Peripheral Artery Disease · Phase 3 · recruiting
- NCT06399900 — ENhancing Exercise With LIGHT to Improve Functioning in PAD · NA · recruiting
- NCT06253312 — Treatment of TASC C and D Aortoiliac Lesions · recruiting
- NCT06165016 — Far Red Light to Improve Functioning in PAD · NA · recruiting
- NCT05804097 — Does Increasing Oxygen Nurture Your Symptomatic Ischemic Ulcer Sufficiently? · Phase 4 · active not recruiting
Other Medical College of Wisconsin trials
Trials by the same sponsor.
- NCT07260552 — Rapid Engagement for Solutions to Population and Outcomes Through Networked Dialogue for Coronary Heart Disease · not yet recruiting
- NCT06795360 — Weight Changes After Incretin-mimetics · NA · not yet recruiting
- NCT07228208 — Role of Endothelial Dysfunction on Exercise Pressor Reflex in Type 2 Diabetes · NA · not yet recruiting
- NCT07298460 — Stimulation-based Therapy to Improve Balance in DCM · Phase 1, PHASE2 · not yet recruiting
- NCT07434544 — Cardiometabolic Effects of Non-Nutritive Sweeteners (NNS) in Type 1 Diabetes (T1D) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05107869 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medical College of Wisconsin
- Last refreshed: 29 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05107869.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing